Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut

Reuters
01 Feb
<a href="https://laohu8.com/S/MAZE">Maze Therapeutics</a> valued at $690.4 million as shares rise marginally in market debut

Jan 31 (Reuters) - Shares of Maze Therapeutics MAZE.O rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.

(Reporting by Ateev Bhandari in Bengaluru; Editing by Alan Barona)

((Ateev.Bhandari@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10